  Transforms Wound Care
  In most cases:
  Eliminates Debridement
    Decreases Pain Medications
    Eliminates Antibiotics
    Simplifies Protocol
    Reduces Suffering

Pending Approval

   Benefits Patients with:
     Diabetes
     Paralysis
   Difficult surgical wounds
     Potentially most wounds

Pending Approval - Kenilin Brand Formulations

What is Kenilin

Upon FDA Approval —

Kenilin will become the simplest way to treat most complex wounds.
Kenilin is an early phase pharmaceutical and management protocol that will be a paradigm shift in wound care.
Kenilin will be used at home with ease by patients putting it on twice a day after being taken off of debridement schedules, antibiotics and pain medications.
Kenilin will allow most patients, even those who have failed months to years of standard care, to heal rapidly.
Kenilin has been used within private practice on 30 worst-case scenario patients (patients on dialysis, diabetic patients, and diabetic patients on dialysis) and shown to work rapdily and easily.
Kenilin brand formulations will be part of a new generation of federally approved combination drugs.

The developers of Kenilin met with the Food and Drug Administration (FDA) in January 2007 for a successful pre-IND meeting. Kenilin is presently on track with Phase 1/Phase 2 research and development.

The FDA published guidelines in 2004 for a new type of combination drugs (pharmaceutical and botanical). Kenilin is not yet approved but is in the process of running approved studies that permit the first human trials to commence at Rose Medical Center, Denver Colorado and State University of New York (Downstate Medical Center, Brooklyn, NY).